Anavex Life Sciences Corp. (AVXL) Given Buy Rating at Maxim Group
Anavex Life Sciences Corp. (NASDAQ:AVXL)‘s stock had its “buy” rating reissued by Maxim Group in a research report issued on Monday. They presently have a $15.00 price objective on the stock. Maxim Group’s price target suggests a potential upside of 361.54% from the company’s previous close.
A number of other research analysts have also weighed in on the company. FBR & Co reissued an “outperform” rating and set a $10.00 target price on shares of Anavex Life Sciences Corp. in a report on Wednesday, October 5th. Zacks Investment Research lowered Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th.
Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at 3.25 on Monday. The firm’s market capitalization is $116.06 million. Anavex Life Sciences Corp. has a 1-year low of $2.43 and a 1-year high of $14.84. The firm’s 50-day moving average price is $3.13 and its 200 day moving average price is $4.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/anavex-life-sciences-corp-avxl-given-buy-rating-at-maxim-group.html
Anavex Life Sciences Corp. (NASDAQ:AVXL) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. On average, analysts predict that Anavex Life Sciences Corp. will post ($0.34) EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in AVXL. Schwab Charles Investment Management Inc. purchased a new stake in Anavex Life Sciences Corp. during the second quarter valued at about $313,000. State Street Corp increased its stake in Anavex Life Sciences Corp. by 349.4% in the second quarter. State Street Corp now owns 88,972 shares of the company’s stock valued at $544,000 after buying an additional 69,172 shares during the period. Rhumbline Advisers purchased a new stake in Anavex Life Sciences Corp. during the second quarter valued at about $192,000. Teachers Advisors Inc. purchased a new stake in Anavex Life Sciences Corp. during the second quarter valued at about $314,000. Finally, American International Group Inc. purchased a new stake in Anavex Life Sciences Corp. during the second quarter valued at about $115,000. Institutional investors and hedge funds own 10.72% of the company’s stock.
Anavex Life Sciences Corp. Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.